COVID-19 outbreak: the gold rush and the responsibilities of the scientific community.
作者信息
Pezzani M D
机构信息
Infectious Diseases Section, Department of Diagnostics and Public Health, University of Verona, Verona, Italy.
出版信息
Clin Microbiol Infect. 2020 Sep;26(9):1123-1124. doi: 10.1016/j.cmi.2020.05.002. Epub 2020 May 15.
Abstract
摘要
相似文献
1
COVID-19 outbreak: the gold rush and the responsibilities of the scientific community.
Clin Microbiol Infect. 2020 Sep;26(9):1123-1124. doi: 10.1016/j.cmi.2020.05.002. Epub 2020 May 15.
2
COVID-19: Stay Cool toward Corticosteroids.
Keio J Med. 2020 Jun 25;69(2):27-29. doi: 10.2302/kjm.2020-0007-LE. Epub 2020 May 30.
3
Targeting SARS-CoV-2 using polycomb inhibitors as antiviral agents.
Epigenomics. 2020 May;12(10):811-812. doi: 10.2217/epi-2020-0154. Epub 2020 Jun 4.
4
COVID-19: Small-Molecule Clinical Trials Landscape.
Curr Top Med Chem. 2020;20(18):1577-1580. doi: 10.2174/156802662018200703154334.
5
[Not Available].
Rev Med Suisse. 2020 Mar 11;16(685):510-511.
6
Lithium for the 2019 novel coronavirus.
Med Hypotheses. 2020 Sep;142:109822. doi: 10.1016/j.mehy.2020.109822. Epub 2020 May 7.
7
A Call for Pediatric COVID-19 Clinical Trials.
Pediatrics. 2020 Aug;146(2). doi: 10.1542/peds.2020-1081. Epub 2020 May 12.
8
Of chloroquine and COVID-19.
Antiviral Res. 2020 May;177:104762. doi: 10.1016/j.antiviral.2020.104762. Epub 2020 Mar 5.
9
Effects of Gene-Eden-VIR and Novirin on SARS-CoV: Implications for COVID-19.
J Evid Based Integr Med. 2020 Jan-Dec;25:2515690X20932523. doi: 10.1177/2515690X20932523.
10
[SARS-CoV-2 protease: an excellent target to develop drugs against COVID-19].
Med Sci (Paris). 2020 Jun-Jul;36(6-7):555-558. doi: 10.1051/medsci/2020106. Epub 2020 Jun 19.
引用本文的文献
1
The ESCMID ethics advisory committee (EEAC): purpose and challenges.
Clin Microbiol Infect. 2022 Apr;28(4):470-471. doi: 10.1016/j.cmi.2022.01.002. Epub 2022 Jan 10.
本文引用的文献
1
Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19.
Clin Infect Dis. 2020 Apr 27. doi: 10.1093/cid/ciaa478.
2
Finding Effective Treatments for COVID-19: Scientific Integrity and Public Confidence in a Time of Crisis.
JAMA. 2020 May 19;323(19):1899-1900. doi: 10.1001/jama.2020.6434.
3
Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review.
JAMA. 2020 May 12;323(18):1824-1836. doi: 10.1001/jama.2020.6019.
4
The many estimates of the COVID-19 case fatality rate.
Lancet Infect Dis. 2020 Jul;20(7):776-777. doi: 10.1016/S1473-3099(20)30244-9. Epub 2020 Mar 27.
5
Treating COVID-19-Off-Label Drug Use, Compassionate Use, and Randomized Clinical Trials During Pandemics.
JAMA. 2020 May 19;323(19):1897-1898. doi: 10.1001/jama.2020.4742.
6
Case-Fatality Rate and Characteristics of Patients Dying in Relation to COVID-19 in Italy.
JAMA. 2020 May 12;323(18):1775-1776. doi: 10.1001/jama.2020.4683.
7
A Novel Coronavirus from Patients with Pneumonia in China, 2019.
N Engl J Med. 2020 Feb 20;382(8):727-733. doi: 10.1056/NEJMoa2001017. Epub 2020 Jan 24.
8
Potential Biases in Estimating Absolute and Relative Case-Fatality Risks during Outbreaks.
PLoS Negl Trop Dis. 2015 Jul 16;9(7):e0003846. doi: 10.1371/journal.pntd.0003846. eCollection 2015.
9
Increasing value and reducing waste in research design, conduct, and analysis.
Lancet. 2014 Jan 11;383(9912):166-75. doi: 10.1016/S0140-6736(13)62227-8. Epub 2014 Jan 8.
Zotero 插件